Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

Lenvatinib (LENV) and atezolizumab/bevacizumab (ATE/BEV) have been approved as first-line regimens for the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to compare their clinical efficacy and safety. Patients receiving ATE/BEV (<i>n</i> = 86) or LENV (<i>n</...

Full description

Bibliographic Details
Main Authors: Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
atezolizumab
bevacizumab
comparison
hepatocellular carcinoma
lenvatinib
Online Access:https://www.mdpi.com/2072-6694/14/7/1747

Similar Items

Similar Items